JP6763770B2 - 自閉症スペクトラム障害のバイオマーカー - Google Patents

自閉症スペクトラム障害のバイオマーカー Download PDF

Info

Publication number
JP6763770B2
JP6763770B2 JP2016525390A JP2016525390A JP6763770B2 JP 6763770 B2 JP6763770 B2 JP 6763770B2 JP 2016525390 A JP2016525390 A JP 2016525390A JP 2016525390 A JP2016525390 A JP 2016525390A JP 6763770 B2 JP6763770 B2 JP 6763770B2
Authority
JP
Japan
Prior art keywords
metabolites
acid
autism
increased
asd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016525390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530504A5 (https=
JP2016530504A (ja
Inventor
ウエスト ポール
ウエスト ポール
イー．バリア ロバート
イー．バリア ロバート
イグナッシュ ローラ
イグナッシュ ローラ
スミス アラン
スミス アラン
バイス プリーティ
バイス プリーティ
Original Assignee
ステミナ バイオマーカー ディスカバリー， インコーポレイテッド
ステミナ バイオマーカー ディスカバリー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステミナ バイオマーカー ディスカバリー， インコーポレイテッド, ステミナ バイオマーカー ディスカバリー， インコーポレイテッド filed Critical ステミナ バイオマーカー ディスカバリー， インコーポレイテッド
Publication of JP2016530504A publication Critical patent/JP2016530504A/ja
Publication of JP2016530504A5 publication Critical patent/JP2016530504A5/ja
Application granted granted Critical
Publication of JP6763770B2 publication Critical patent/JP6763770B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2016525390A 2013-07-09 2014-07-03 自閉症スペクトラム障害のバイオマーカー Expired - Fee Related JP6763770B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361844128P 2013-07-09 2013-07-09
US61/844,128 2013-07-09
US201461996835P 2014-05-14 2014-05-14
US61/996,835 2014-05-14
PCT/US2014/045397 WO2015006160A2 (en) 2013-07-09 2014-07-03 Biomarkers of autism spectrum disorder

Publications (3)

Publication Number Publication Date
JP2016530504A JP2016530504A (ja) 2016-09-29
JP2016530504A5 JP2016530504A5 (https=) 2017-07-27
JP6763770B2 true JP6763770B2 (ja) 2020-09-30

Family

ID=52280698

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016525390A Expired - Fee Related JP6763770B2 (ja) 2013-07-09 2014-07-03 自閉症スペクトラム障害のバイオマーカー

Country Status (6)

Country Link
US (2) US10060932B2 (https=)
EP (1) EP3019624B1 (https=)
JP (1) JP6763770B2 (https=)
CA (1) CA2917483A1 (https=)
MX (1) MX2016000293A (https=)
WO (1) WO2015006160A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
WO2017197252A1 (en) * 2016-05-13 2017-11-16 Stemina Biomarker Discovery, Inc. Autism subsets
JP6978122B2 (ja) 2017-03-31 2021-12-08 アキシャル セラピューティクス，インク． 自閉症および関連障害の治療および予防のための腸管選択的隔離剤
US12080432B1 (en) 2017-06-01 2024-09-03 The Regents Of The University Of Colorado Plasma metabolome as a predictor of biological aging
WO2019148189A1 (en) * 2018-01-29 2019-08-01 Stemina Biomarker Discovery, Inc. Diagnosis and treatment of autism spectrum disorders based on amine containing metabotypes
CN109813912B (zh) * 2019-01-04 2021-12-28 深圳大学 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用
WO2020206444A1 (en) 2019-04-05 2020-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic for childhood risk of autism spectrum disorder
CN113906296B (zh) * 2019-04-23 2024-11-15 中国医学科学院北京协和医院 基于机器学习的使用代谢物作为标记物的孤独症谱系障碍诊断方法和装置
US20240210423A1 (en) * 2019-05-02 2024-06-27 Stemina Biomarker Discovery, Inc. Diagnosis and treatment of autism spectrum disorders associated with altered metabolic pathways
EP3980764A4 (en) * 2019-06-06 2023-07-05 Icahn School of Medicine at Mount Sinai SYSTEMS AND METHODS FOR DIAGNOSIS OF BIOLOGICAL DISEASES RELATED TO PERIODIC VARIATIONS OF METAL METABOLISM
US20220146527A1 (en) * 2019-09-17 2022-05-12 Chang Gung University Method of creating characteristic profiles of mass spectra and identification model for analyzing and identifying features of microorganisms
EP4041265A4 (en) * 2019-10-11 2024-03-27 Stemina Biomarker Discovery, Inc. DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDERS ASSOCIATED WITH ALTERED LEVELS OF METABOLITES CONCENTRATIONS
US20240369538A1 (en) * 2019-10-16 2024-11-07 Rene Anand Live Virus Vaccine Injury Risk
CN116547520A (zh) * 2020-09-21 2023-08-04 分子优公司 孤独症谱系障碍的诊断与治疗方法
WO2022056646A1 (en) * 2020-09-21 2022-03-24 Molecular You Corporation Method of diagnosis and treatment of autism spectrum disorder
CN116391128B (zh) * 2020-10-24 2025-11-21 巴塞尔大学医院 人血浆中麦角酸二乙基酰胺（lsd）和2,3-二氢-3-羟基-2-氧代麦角二乙胺（o-h-lsd）的定量方法
EP4012414A1 (en) * 2020-12-11 2022-06-15 Stalicla S.A. Diagnosis of autism spectrum disorder phenotype 1
CN113125588B (zh) * 2021-03-17 2022-01-14 广东省农业科学院农业质量标准与监测技术研究所 一种代谢组学分析技术判别鸭屎香单丛茶时空分类的应用
KR102530345B1 (ko) * 2021-08-04 2023-05-10 단국대학교 천안캠퍼스 산학협력단 대사체 프로파일링을 이용한 자폐 스펙트럼 장애의 진단용 조성물 및 이를 포함하는 진단키트
JP2024134052A (ja) * 2023-03-20 2024-10-03 株式会社島津製作所 データ処理方法、データ処理装置およびプログラム

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686311A (en) * 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
US6708064B2 (en) * 2000-02-24 2004-03-16 Ali R. Rezai Modulation of the brain to affect psychiatric disorders
AU2001253886A1 (en) 2000-04-12 2001-10-30 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
US20020009740A1 (en) 2000-04-14 2002-01-24 Rima Kaddurah-Daouk Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20080154332A1 (en) * 2001-12-24 2008-06-26 The Cleveland Clinic Foundation Modulation of the Brain to Affect Psychiatric Disorders and Functions
US8131473B1 (en) 2004-05-20 2012-03-06 Metabolon, Inc. Data analysis methods for locating entities of interest within large, multivariable datasets
GB0504096D0 (en) 2005-02-28 2005-04-06 Tipogen As Method
US7604948B2 (en) * 2005-05-05 2009-10-20 The Regents Of The University Of California Biomarkers for diagnosing an autism spectrum disorder
US20070023677A1 (en) 2005-06-29 2007-02-01 Perkins Patrick D Multimode ionization source and method for screening molecules
US7949475B2 (en) 2005-08-08 2011-05-24 Metabolon Inc. System and method for analyzing metabolomic data
CA2618123C (en) 2005-08-08 2013-04-02 Metabolon Inc. A system, method, and computer program product using a database in a computing system to compile and compare metabolomic data obtained from a plurality of samples
JP5496650B2 (ja) 2006-03-21 2014-05-21 メタボロン インコーポレイテッド サンプル内の個々の要素を識別及び定量化するために分光測定データを分析するシステム、方法及びコンピュータプログラム製品
WO2008124187A1 (en) 2007-04-10 2008-10-16 University Of Medicine And Dentistry Of Nj Biochemical markers for disease states and genes for identification of biochemical defects
JP5306345B2 (ja) * 2007-07-26 2013-10-02 フェノメノーム ディスカバリーズ インク 自閉症スペクトラム障害の診断、リスク評価、及びモニタリングを行うための方法
WO2009032722A1 (en) * 2007-08-29 2009-03-12 The Cleveland Clinic Foundation Carbamylated proteins and risk of cardiovascular disease
US7884318B2 (en) 2008-01-16 2011-02-08 Metabolon, Inc. Systems, methods, and computer-readable medium for determining composition of chemical constituents in a complex mixture
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
DK200970026A (en) 2009-06-12 2010-12-13 Alfa Laval Corp Ab A centrifugal separator
EP2309276A1 (en) * 2009-09-22 2011-04-13 One Way Liver Genomics, S.L. Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
JP5814337B2 (ja) * 2010-03-22 2015-11-17 ステミナ バイオマーカー ディスカバリー， インコーポレイテッド ヒト幹細胞様細胞及びメタボロミクスを使用した医薬のヒト発生毒性の予測
WO2011139914A1 (en) 2010-04-29 2011-11-10 Wisconsin Alumni Research Foundation Metabolic biomarkers of autism
WO2011146683A1 (en) * 2010-05-19 2011-11-24 Metabolon, Inc. Methods and reagents for metabolomics and histology in a biological sample and a kit for the same
US20130217647A1 (en) * 2010-07-28 2013-08-22 Metabolon, Inc. Biomarkers for Prostate Cancer and Methods Using the Same
WO2013016700A1 (en) * 2011-07-27 2013-01-31 The Research Foundation Of State University Of New York Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc
US20140303228A1 (en) * 2011-10-18 2014-10-09 Metabolon, Inc. Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same
CA2853202A1 (en) * 2011-12-09 2013-06-13 Metabolon, Inc. Biomarkers for kidney cancer and methods using the same
WO2014036182A2 (en) * 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
MX2015003642A (es) 2012-09-21 2016-07-11 Univ Toronto Cmpf como biomarcador para diabetes y metodos asociados.
HUE043604T2 (hu) * 2012-11-02 2019-08-28 Stemina Biomarker Discovery Inc Gyógyszerek humán fejlõdési toxicitásának elõrejelzésére humán õsjellegû sejtek és metabolomikus arányok alkalmazásával
WO2014120449A1 (en) * 2013-01-31 2014-08-07 Metabolon, Inc. Biomarkers related to insulin resistance progression and methods using the same
US9176113B1 (en) * 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) * 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk

Also Published As

Publication number Publication date
US20160169915A1 (en) 2016-06-16
JP2016530504A (ja) 2016-09-29
US11268966B2 (en) 2022-03-08
MX2016000293A (es) 2016-06-21
EP3019624B1 (en) 2020-09-16
US10060932B2 (en) 2018-08-28
WO2015006160A3 (en) 2015-11-26
EP3019624A4 (en) 2017-01-11
US20190072569A1 (en) 2019-03-07
CA2917483A1 (en) 2015-01-15
EP3019624A2 (en) 2016-05-18
WO2015006160A2 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
JP6763770B2 (ja) 自閉症スペクトラム障害のバイオマーカー
West et al. Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children
Roede et al. Serum metabolomics of slow vs. rapid motor progression Parkinson’s disease: a pilot study
Franzosa et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease
Han et al. Profiling novel metabolic biomarkers for Parkinson's disease using in‐depth metabolomic analysis
Mapstone et al. Plasma phospholipids identify antecedent memory impairment in older adults
Bunning et al. Global metabolic profiling to model biological processes of aging in twins
Weiss et al. Metabolomics in the study of kidney diseases
AU2016204969B2 (en) Metabolic biomarkers of autism
Kurbatova et al. Urinary metabolic phenotyping for Alzheimer’s disease
US20190178900A1 (en) Autism subsets
Pereira et al. Multiomics implicate gut microbiota in altered lipid and energy metabolism in Parkinson’s disease
Vardarajan et al. Differences in plasma metabolites related to Alzheimer's disease, APOE ε4 status, and ethnicity
Jernbom Falk et al. Autoantibody profiles associated with clinical features in psychotic disorders
de Lope et al. Comprehensive blood metabolomics profiling of Parkinson’s disease reveals coordinated alterations in xanthine metabolism
Bereman et al. Metabolite profiling reveals predictive biomarkers and the absence of β-methyl amino-l-alanine in plasma from individuals diagnosed with amyotrophic lateral sclerosis
JP7643598B2 (ja) 取得方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システム
Navas-Carrillo et al. Novel biomarkers in Alzheimer’s disease using high resolution proteomics and metabolomics: miRNAS, proteins and metabolites
Kong et al. Assessment of coverage for endogenous metabolites and exogenous chemical compounds using an untargeted metabolomics platform
US20240118291A1 (en) Diagnosis and treatment of autism spectrum disorders using altered ratios of metabolic concentrations
Patel Role of proteomics in biomarker discovery and psychiatric disorders: current status, potentials, limitations and future challenges
Tkachev et al. Differences in lipidome and metabolome organization of prefrontal cortex among human populations
JP2017536543A (ja) 遺伝的変異体の影響を決定するためのシステム、方法、および装置
Gallo Seeking Molecular Biomarkers for Schizophrenia Using ROC Analysis
Kaddurah-Daouk et al. Metabolomics: a global biochemical approach to the discovery of biomarkers for psychiatric disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200729

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200811

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200910

R150 Certificate of patent or registration of utility model

Ref document number: 6763770

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees